[go: up one dir, main page]

MX2018008469A - Metodos y dispositivos para tratar trastornos oculares posteriores con aflibercept y otros productos biologicos. - Google Patents

Metodos y dispositivos para tratar trastornos oculares posteriores con aflibercept y otros productos biologicos.

Info

Publication number
MX2018008469A
MX2018008469A MX2018008469A MX2018008469A MX2018008469A MX 2018008469 A MX2018008469 A MX 2018008469A MX 2018008469 A MX2018008469 A MX 2018008469A MX 2018008469 A MX2018008469 A MX 2018008469A MX 2018008469 A MX2018008469 A MX 2018008469A
Authority
MX
Mexico
Prior art keywords
devices
end portion
methods
medicament container
disorderswith
Prior art date
Application number
MX2018008469A
Other languages
English (en)
Inventor
Patel Samirkumar
Original Assignee
Clearside Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clearside Biomedical Inc filed Critical Clearside Biomedical Inc
Publication of MX2018008469A publication Critical patent/MX2018008469A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

La presente invención se refiere a métodos y dispositivos para tratar la AMD húmeda, CNV, AMD húmeda asociada con CNV y/o AMD húmeda asociada con RVO en un sujeto humano que lo necesite. En ciertos aspectos, los dispositivos que sé proporcionan en la presente incluyen un recipiente de medicamento que define un lumen configurado para contener un medicamento, una porción del extremo distante del recipiente de medicamento que incluye una porción de acoplamiento configurada para acoplarse de manera desmontable a un conjunto de aguja, una porción del extremo próximo del recipiente de medicamento que incluye una pestaña y un hombro longitudinal; un conjunto de pistón que incluye una porción del extremo distante dispuesta de manera móvil dentro del lumen del recipiente de medicamento; y un asa acoplada a una porción del extremo próximo del conjunto de pistón.
MX2018008469A 2016-01-08 2017-01-09 Metodos y dispositivos para tratar trastornos oculares posteriores con aflibercept y otros productos biologicos. MX2018008469A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662276543P 2016-01-08 2016-01-08
US201662324708P 2016-04-19 2016-04-19
PCT/US2017/012757 WO2017120601A1 (en) 2016-01-08 2017-01-09 Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics

Publications (1)

Publication Number Publication Date
MX2018008469A true MX2018008469A (es) 2018-11-09

Family

ID=59274052

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008469A MX2018008469A (es) 2016-01-08 2017-01-09 Metodos y dispositivos para tratar trastornos oculares posteriores con aflibercept y otros productos biologicos.

Country Status (9)

Country Link
EP (1) EP3400014A1 (es)
JP (1) JP2019501200A (es)
KR (1) KR20180101488A (es)
CN (1) CN108778330A (es)
AU (1) AU2017206114A1 (es)
BR (1) BR112018013805A2 (es)
CA (1) CA3010862A1 (es)
MX (1) MX2018008469A (es)
WO (1) WO2017120601A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
EP2627292B1 (en) 2010-10-15 2018-10-10 Clearside Biomedical, Inc. Device for ocular access
CN110893188A (zh) 2012-11-08 2020-03-20 克莱尔塞德生物医学股份有限公司 用于在人类受试者中治疗眼部疾病的方法和装置
CN116327482A (zh) 2013-05-03 2023-06-27 科尼尔赛德生物医学公司 用于眼部注射的设备和方法
US10188550B2 (en) 2013-06-03 2019-01-29 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
CN105555311B (zh) 2013-07-23 2021-10-08 诺瓦利克有限责任公司 稳定的抗体组合物
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2017055454A1 (en) 2015-09-30 2017-04-06 Novaliq Gmbh Semifluorinated compounds and their compositions
CN108712911A (zh) 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
EP3452103A1 (en) 2016-04-15 2019-03-13 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
JP2019514581A (ja) 2016-05-02 2019-06-06 クリアサイド バイオメディカル，インコーポレイテッド 眼の薬物送達のためのシステムおよび方法
US10973681B2 (en) 2016-08-12 2021-04-13 Clearside Biomedical, Inc. Devices and methods for adjusting the insertion depth of a needle for medicament delivery
US12090294B2 (en) 2017-05-02 2024-09-17 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
EP3687464A4 (en) * 2017-09-27 2021-09-29 REGENXBIO Inc. TREATMENT OF EYE DISEASES WITH A TOTALLY HUMAN POST-TRANSLATION MODIFIED ANTI-VEGF FAB
CN111511361A (zh) * 2017-12-20 2020-08-07 安杰斯制药公司 作为多激酶抑制剂的胺基碳酸盐及尿素化合物
CN108030783A (zh) * 2017-12-27 2018-05-15 广东众生药业股份有限公司 乐伐替尼在制备防治黄斑变性的药物中的用途
WO2019169341A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
IL318714A (en) * 2018-05-10 2025-03-01 Regeneron Pharma Formulations that include high concentrations of VEGF receptor fusion protein
CN110693886B (zh) * 2018-07-09 2022-12-06 天津医科大学 防治脑海绵状血管畸形病变的药物
WO2020127641A1 (fr) * 2018-12-20 2020-06-25 Laboratoires Thea Composition ophtalmique nutraceutique pour le traitement de pathologies retiniennes a composante neovasculaire
WO2020165132A1 (en) * 2019-02-13 2020-08-20 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
KR20200101160A (ko) * 2019-02-19 2020-08-27 전남대학교산학협력단 리보세라닙을 포함하는 안구 신생혈관 억제용 약학 조성물 및 이를 이용한 안구 신생혈관 억제 방법
JP2022521851A (ja) * 2019-04-03 2022-04-12 レジェンクスバイオ インコーポレーテッド 眼の病態に対する遺伝子療法
CN110522909B (zh) * 2019-09-30 2024-02-20 安徽省立医院 一种协同增强抗her2阳性肿瘤效果的药物组合
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021093764A1 (en) * 2019-11-11 2021-05-20 Cstone Pharmaceuticals (Suzhou) Co., Ltd. Pharmaceutical combination and use thereof
WO2021123142A1 (en) * 2019-12-19 2021-06-24 Active Biotech Ab Compounds for treatment of eye diseases associated with excessive vascularisation
CN115697333A (zh) * 2020-02-19 2023-02-03 科尼尔赛德生物医学公司 包含阿西替尼的组合物和治疗眼部疾病的方法
EP4164593A1 (en) * 2020-06-15 2023-04-19 OPKO Pharmaceuticals, LLC Triamcinolone acetonide-loaded liposomes topical ophthalmic formulations as primary therapy for macular edema secondary to branch retinal vein occlusion
WO2022245739A1 (en) * 2021-05-17 2022-11-24 Regeneron Pharmaceuticals, Inc. Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
CN113546176B (zh) * 2021-06-30 2024-03-15 南通大学 一种特异性用于抑制眼内血管新生药物合成方法
CN116087525B (zh) * 2022-11-16 2025-10-28 东南大学 一种即时检测Tau蛋白的微腔结构高灵敏SERS芯片的制备方法
CN118356501A (zh) * 2023-01-19 2024-07-19 百奥泰生物制药股份有限公司 一种复方制剂及其应用
WO2024167694A2 (en) * 2023-02-06 2024-08-15 Celularity Inc. Placental extracellular matrices for ocular delivery of ophthalmic therapeutic agents
JP2025003405A (ja) * 2023-06-23 2025-01-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 眼内血管新生性疾患の治療のための、ｖｅｇｆアンタゴニストの延長された高用量レジメン
WO2026003803A1 (en) * 2024-06-28 2026-01-02 Kyowa Kirin Co., Ltd. Tivozanib for treating posterior segment eye diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014516986A (ja) * 2011-05-27 2014-07-17 ノバルティス アーゲー 視覚疾患の治療方法
US20150037422A1 (en) * 2012-02-22 2015-02-05 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
CN110893188A (zh) * 2012-11-08 2020-03-20 克莱尔塞德生物医学股份有限公司 用于在人类受试者中治疗眼部疾病的方法和装置
WO2015095772A2 (en) * 2013-12-20 2015-06-25 Emory University Formulations and methods for targeted ocular delivery of therapeutic agents
EP3157463A4 (en) * 2014-06-17 2018-02-21 Clearside Biomedical, Inc. Methods and devices for treating posterior ocular disorders

Also Published As

Publication number Publication date
KR20180101488A (ko) 2018-09-12
BR112018013805A2 (pt) 2018-12-11
CN108778330A (zh) 2018-11-09
CA3010862A1 (en) 2017-07-13
WO2017120601A1 (en) 2017-07-13
EP3400014A1 (en) 2018-11-14
AU2017206114A1 (en) 2018-08-02
JP2019501200A (ja) 2019-01-17

Similar Documents

Publication Publication Date Title
MX2018008469A (es) Metodos y dispositivos para tratar trastornos oculares posteriores con aflibercept y otros productos biologicos.
MX2016016836A (es) Metodos y dispositivos para tratar trastornos oculares posteriores.
PH12014502792A1 (en) Soft tip cannula
MX2017000920A (es) Dispositivos magneticos para anastomosis y metodos de entrega.
MX2016016070A (es) Introductor y guia de cateter con aguja tangencial subretinal.
WO2015164839A3 (en) System and method for safety syringe
MX2020008980A (es) Dispositivo de administracion de farmacos.
EP4324414A3 (en) Devices and methods for treating the skin using a rollerball or a wicking member
WO2014127389A3 (en) Thrombectomy catheter
NZ630742A (en) A patient interface
MX2016017028A (es) Canula de diametro variable y metodos para el control de la profundidad de insercion para administracion de medicamentos.
GB201318950D0 (en) Deployment Catheter
BR112015017366A2 (pt) dispositivo médico e método para facilitar a seleção de um implante de anuloplastia
MY182497A (en) Ocular implant delivery device and method
EP4374873A3 (en) Methods for treating or preventing opthalmological conditions
MX2020011003A (es) Valvula para dilatador y ensamble de cubierta.
MX2017001673A (es) Prenda de compresion medica terapeutica y metodo.
CO6500125A1 (es) Suministro de curcumina por derivacion
SG10201807789WA (en) Vaginal composition and use thereof
MX384815B (es) Dispositivo para insertar una canula de punta roma bajo la piel de un paciente.
WO2017079325A3 (en) Injection devices and systems and methods for using them
WO2016123496A3 (en) Suspension implant
MX2015011418A (es) Tratamiento de enfermedades con nanofibras de poli-n-acetilglucosamina.
IN2014DN07443A (es)
TN2014000494A1 (en) Disposable syringe and push rod for the same